Sarepta Community Update on LGMD Programs

Sarepta Therapeutics recently published a Community Letter to share updates on their limb-girdle muscular dystrophy gene therapy programs.

Click here to access the letter on Sarepta’s website.

Sarepta is enrolling participants in their LGMD2A/R1 natural history study cohort while simultaneously advancing their preclinical (animal/cell) work. For further information on the natural history study, go to https://clinicaltrials.sarepta.com/journeyLGMD

Sarepta expects to give their next broad update on all LGMD programs at the International LGMD Conference, July 2025 in Orlando, Florida.

Questions for the Sarepta team can be directed to advocacy@sarepta.com